# 04_QA_REPORT.md

# Quality Assurance Report

## Identity

  -----------------------------------------------------------------------
  Field                               Value
  ----------------------------------- -----------------------------------
  QA ID                               QA-PP-0210

  PP ID                               PP-0210

  Title                               HER2-targeted Therapy for Gastric
                                      Adenocarcinoma

  Version                             1.0.0

  Status                              GOLD

  Production Basis                    Approved and Locked PP-0210
                                      Decision Batch

  Source Basis                        Project Source Files

  Governance                          CORE_WORKING_RULES v1.7

  Gold Specification                  FREEZE GOLD POPULATION PACKAGE
                                      SPECIFICATION v1.1
  -----------------------------------------------------------------------

------------------------------------------------------------------------

# QA Executive Conclusion

PP-0210 is internally coherent as the **HER2-specific treatment-modality
Population Package**.

The package maintains the approved hierarchy:

**HER2 Testing**

→ **Biomarker-Directed Treatment Selection**

→ **HER2-targeted Therapy**

→ **Trastuzumab / T-DXd**

→ **drug-, toxicity-, monitoring-, resistance-, and trial-specific
packages**

No major architecture blocker was identified.

------------------------------------------------------------------------

# Layer 1 --- Content QA

## 1.1 Identity Check

### Requirement

The package must answer the locked PP identity.

### Finding

PP-0210 is consistently identified as:

**HER2-targeted Therapy for Gastric Adenocarcinoma.**

The package does not drift into generic targeted therapy.

### Result

**PASS**

------------------------------------------------------------------------

## 1.2 Atomic Question Check

### Requirement

One PP answers one clinical educational question.

### Finding

The package answers:

> What is HER2-targeted therapy for gastric adenocarcinoma, how does
> HER2 status connect to treatment, what are the major HER2-directed
> treatment approaches, and what should patients understand about
> benefit, limitations, safety, and treatment context?

No second competing educational question was introduced.

### Result

**PASS**

------------------------------------------------------------------------

## 1.3 Content Completeness

The package includes:

-   HER2 treatment relevance;
-   relationship with testing;
-   trastuzumab;
-   T-DXd;
-   chemotherapy combination;
-   immunotherapy combination;
-   pivotal evidence;
-   benefit;
-   limitations;
-   resistance;
-   safety;
-   patient questions;
-   Knowledge Graph;
-   boundary.

### Result

**PASS**

------------------------------------------------------------------------

## 1.4 Patient-Facing Depth

The package explains:

-   what HER2 means;
-   why testing matters;
-   why HER2 positivity does not determine one drug;
-   why targeted therapy can be combined with chemotherapy;
-   why response is not guaranteed;
-   why safety monitoring matters;
-   why treatment history matters.

### Result

**PASS**

------------------------------------------------------------------------

## 1.5 Common Misconception Coverage

The CKO explicitly corrects:

-   HER2-positive = automatic trastuzumab;
-   targeted therapy = chemotherapy-free;
-   all HER2 drugs are identical;
-   positive biomarker = guaranteed response;
-   targeted therapy = harmless;
-   trastuzumab failure = no HER2 options;
-   HER2-negative = no treatment;
-   biomarker = automatic prescription;
-   targeted = cancer-cell-only toxicity;
-   response = permanent cure.

### Result

**PASS**

------------------------------------------------------------------------

# Layer 2 --- Clinical QA

## 2.1 Guideline Alignment

### Requirement

Clinical treatment content must remain consistent with supplied
disease-specific guidance.

### Finding

The package follows the supplied NCCN architecture:

-   HER2-positive advanced disease;
-   trastuzumab-containing first-line therapy;
-   selected pembrolizumab + trastuzumab + chemotherapy;
-   subsequent T-DXd.

### Result

**PASS**

------------------------------------------------------------------------

## 2.2 ToGA Integrity

The package preserves:

-   HER2-positive advanced gastric/GEJ context;
-   trastuzumab + chemotherapy;
-   randomized phase III evidence;
-   reported OS benefit;
-   distinction between trial-level evidence and individual prediction.

### Result

**PASS**

------------------------------------------------------------------------

## 2.3 KEYNOTE-811 Integrity

The package preserves:

-   HER2-positive advanced disease;
-   trastuzumab;
-   chemotherapy;
-   pembrolizumab;
-   selected combination context.

It does not turn PP-0210 into an immunotherapy-selection package.

### Result

**PASS**

------------------------------------------------------------------------

## 2.4 DESTINY-Gastric01 Integrity

The package preserves:

-   previously treated HER2-positive advanced gastric/EGJ
    adenocarcinoma;
-   prior trastuzumab-containing treatment;
-   T-DXd;
-   randomized comparison;
-   meaningful response/OS/PFS evidence;
-   important toxicity including ILD/pneumonitis.

### Result

**PASS**

------------------------------------------------------------------------

## 2.5 DESTINY-Gastric02 Integrity

The package uses the trial as complementary evidence for subsequent
T-DXd treatment in a Western population.

No unsupported universal extrapolation is made.

### Result

**PASS**

------------------------------------------------------------------------

## 2.6 Treatment-Line Integrity

The package distinguishes:

-   first-line trastuzumab-based treatment;
-   subsequent-line T-DXd.

It does not collapse all HER2-directed therapy into one undifferentiated
treatment pathway.

### Result

**PASS**

------------------------------------------------------------------------

## 2.7 HER2 Testing Boundary

The package states that HER2 testing is required for treatment relevance
but delegates detailed testing.

It does not reproduce:

-   IHC scoring;
-   ISH/FISH methodology;
-   laboratory workflow.

### Result

**PASS**

------------------------------------------------------------------------

## 2.8 Predictive / Prognostic Boundary

The package does not claim that HER2 positivity automatically determines
prognosis.

It correctly centers the treatment-predictive role.

### Result

**PASS**

------------------------------------------------------------------------

## 2.9 Safety Integrity

The package includes:

-   cardiac considerations with trastuzumab;
-   ILD/pneumonitis awareness with T-DXd;
-   general principle that targeted therapy is not toxicity-free.

It does not provide detailed management algorithms.

### Result

**PASS**

------------------------------------------------------------------------

## 2.10 Individualized Treatment Safety

The package does not tell a patient:

-   which drug to start;
-   when to stop;
-   when to switch;
-   what dose to use;
-   when to repeat testing.

### Result

**PASS**

------------------------------------------------------------------------

# Layer 3 --- Educational QA

## 3.1 Plain-Language Requirement

Technical terms are introduced with explanatory context.

Examples:

-   HER2;
-   monoclonal antibody;
-   antibody-drug conjugate;
-   resistance;
-   treatment line;
-   ILD/pneumonitis.

### Result

**PASS**

------------------------------------------------------------------------

## 3.2 One Concept Per Paragraph

The CKO uses discrete clinical knowledge blocks rather than one
continuous dense narrative.

### Result

**PASS**

------------------------------------------------------------------------

## 3.3 Patient-Centeredness

The package explains why the information matters to patients.

It does not merely reproduce guideline language.

### Result

**PASS**

------------------------------------------------------------------------

## 3.4 Neutrality

The package avoids:

-   promotional language;
-   absolute claims;
-   guaranteed outcomes;
-   universal superiority claims.

### Result

**PASS**

------------------------------------------------------------------------

## 3.5 Benefit-Risk Balance

Benefits and limitations are both represented.

The package explicitly communicates:

> meaningful treatment benefit can coexist with meaningful toxicity.

### Result

**PASS**

------------------------------------------------------------------------

## 3.6 Misconception Control

The package proactively corrects clinically important misconceptions.

### Result

**PASS**

------------------------------------------------------------------------

# Layer 4 --- Governance QA

## 4.1 Source-First Compliance

The package was built after searching the Source Files for:

-   PP identity;
-   Gold Discussion reference;
-   Gold artifact references;
-   governance;
-   PP Registry;
-   HER2 clinical evidence.

This follows WR-011 and WR-011A. fileciteturn47file12L1-L15

### Result

**PASS**

------------------------------------------------------------------------

## 4.2 User-Controlled Sequence

The production was triggered by the explicit request:

**PP-0210 --- HER2-targeted Therapy**

No PP was selected or advanced automatically.

### Result

**PASS**

------------------------------------------------------------------------

## 4.3 Immediate Production

The Decision Batch was already approved and locked.

The four-artifact package was therefore produced without asking again
about:

-   format;
-   depth;
-   artifact structure;
-   ZIP;
-   naming.

This follows WR-010 and WR-010A. fileciteturn46file11L1-L15

### Result

**PASS**

------------------------------------------------------------------------

## 4.4 Four-Artifact Requirement

The package contains:

1.  `01_CKO.md`
2.  `02_KNOWLEDGE_PASSPORT.md`
3.  `03_PRIMARY_EVIDENCE_PACKAGE.md`
4.  `04_QA_REPORT.md`

This is the required Gold structure. fileciteturn47file13L1-L15

### Result

**PASS**

------------------------------------------------------------------------

## 4.5 Boundary Requirement

The final production response contains one clean Boundary with:

-   Core;
-   Supporting;
-   Explicitly Excluded;
-   Delegated-to PP.

This follows WR-010C. fileciteturn46file11L1-L15

### Result

**PASS**

------------------------------------------------------------------------

# Adjacent PP Overlap QA

## PP-0181 --- HER2 Testing

### Ownership

HER2 testing and interpretation.

### PP-0210

Therapeutic meaning of the HER2 result.

### Result

**PASS --- boundary clean**

------------------------------------------------------------------------

## PP-0190 --- Biomarker-Directed Treatment Selection

### Ownership

General biomarker-to-treatment decision.

### PP-0210

HER2-specific treatment modality.

### Result

**PASS --- boundary clean**

------------------------------------------------------------------------

## PP-0209 --- Targeted Therapy

### Ownership

Targeted therapy as a general modality.

### PP-0210

HER2-specific targeted therapy.

### Result

**PASS --- hierarchical specialization**

------------------------------------------------------------------------

## Trastuzumab

### Ownership

Drug-specific knowledge.

### PP-0210

Foundational place of trastuzumab within HER2-targeted therapy.

### Result

**PASS**

------------------------------------------------------------------------

## T-DXd

### Ownership

Drug-specific knowledge.

### PP-0210

Foundational place of T-DXd within HER2-targeted therapy.

### Result

**PASS**

------------------------------------------------------------------------

## HER2 Resistance

### Ownership

Detailed resistance biology and management.

### PP-0210

Resistance as a treatment limitation.

### Result

**PASS**

------------------------------------------------------------------------

## Cardiac Monitoring

### Ownership

Detailed cardiac surveillance.

### PP-0210

Cardiac safety awareness.

### Result

**PASS**

------------------------------------------------------------------------

## HER2 Toxicities

### Ownership

Detailed toxicity.

### PP-0210

Safety awareness.

### Result

**PASS**

------------------------------------------------------------------------

# Knowledge Graph QA

## Prerequisite Nodes

-   HER2 Biology
-   HER2 Testing
-   Biomarker-Directed Treatment Selection
-   Targeted Therapy

### Result

**PASS**

## Downstream Nodes

-   Trastuzumab
-   T-DXd
-   ADC
-   ADC Mechanism
-   ToGA
-   DESTINY-Gastric
-   HER2 Resistance
-   Cardiac Monitoring
-   HER2 Toxicities
-   Combination Therapy
-   ILD/Pneumonitis

### Result

**PASS**

------------------------------------------------------------------------

# Evidence Traceability QA

## Claim Category 1 --- Treatment Architecture

Source:

NCCN Gastric Cancer v2.2026.

Result:

**PASS**

## Claim Category 2 --- ToGA

Sources:

NCCN and NCI.

Result:

**PASS**

## Claim Category 3 --- KEYNOTE-811

Sources:

NCCN and NCI.

Result:

**PASS**

## Claim Category 4 --- T-DXd

Sources:

NCCN, NCI, DESTINY-Gastric evidence.

Result:

**PASS**

## Claim Category 5 --- Patient-Facing Safety

Sources:

NCI and ACS.

Result:

**PASS**

------------------------------------------------------------------------

# Evidence Proportionality QA

## High-depth evidence

-   HER2-targeted treatment concept;
-   trastuzumab;
-   ToGA;
-   T-DXd;
-   DESTINY-Gastric01;
-   KEYNOTE-811.

## Moderate-depth evidence

-   DESTINY-Gastric02;
-   HER2 heterogeneity;
-   treatment-line context;
-   safety principles.

## Supporting evidence

-   biosimilar concept;
-   EGJ context;
-   clinical trial context.

This is proportional to the clinical importance of each component.

### Result

**PASS**

------------------------------------------------------------------------

# Gold Depth QA

## Requirement

The package must not be compacted below the approved Gold standard.

The Gold specification states that Gold Reference Packages establish
minimum production depth and that future packages shall not be
shortened, compressed, or materially reduced in reasoning, evidence, QA,
Knowledge Graph, or patient-facing depth. fileciteturn47file13L1-L15

## Finding

The four artifacts preserve:

-   full CKO clinical reasoning;
-   patient-facing explanation;
-   Knowledge Passport runtime routing;
-   source hierarchy;
-   evidence matrix;
-   evidence notes;
-   evidence limitations;
-   future update triggers;
-   boundary verification;
-   substantive QA;
-   adjacent-package overlap;
-   Knowledge Graph relationships.

### Result

**PASS --- GOLD DEPTH**

------------------------------------------------------------------------

# Cross-Artifact Consistency QA

## CKO ↔ KP

Both identify PP-0210 as the HER2-specific treatment-modality node.

**PASS**

## CKO ↔ EP

Clinical claims in the CKO are represented in the evidence package.

**PASS**

## CKO ↔ QA

The QA report evaluates the same scope represented in the CKO.

**PASS**

## KP ↔ EP

Runtime retrieval rules align with evidence ownership.

**PASS**

## EP ↔ QA

Evidence hierarchy and source limitations are reflected in QA.

**PASS**

------------------------------------------------------------------------

# Safety QA

## Potentially Unsafe Pattern

"HER2-positive means you should receive trastuzumab."

### Corrected

HER2 positivity may make HER2-directed treatment relevant; the actual
treatment depends on clinical context.

**PASS**

## Potentially Unsafe Pattern

"T-DXd is the treatment after trastuzumab."

### Corrected

T-DXd is an important subsequent HER2-directed option for selected
patients after prior treatment.

**PASS**

## Potentially Unsafe Pattern

"Targeted therapy has fewer serious side effects."

### Corrected

Targeted therapies have treatment-specific risks and can cause serious
toxicity.

**PASS**

## Potentially Unsafe Pattern

"ILD is uncommon, so it is not important."

### Corrected

ILD/pneumonitis is an important serious safety consideration with T-DXd.

**PASS**

------------------------------------------------------------------------

# Maintenance QA

PP-0210 should be reviewed when:

-   HER2 treatment recommendations change;
-   new HER2 agents become standard;
-   new pivotal trials alter the evidence;
-   treatment-line positioning changes;
-   safety signals emerge;
-   HER2 testing requirements change;
-   downstream package ownership changes.

### Result

**PASS**

------------------------------------------------------------------------

# Repository Readiness QA

Required artifact files:

-   present;
-   correctly named;
-   internally consistent.

ZIP:

-   contains all four artifacts;
-   uses PP number and full package title;
-   Gold version naming preserved.

### Result

**PASS**

------------------------------------------------------------------------

# Final Four-Artifact Audit

  Requirement                    CKO   KP   EP   QA
  ---------------------------- ----- ---- ---- ----
  Identity                         ✓    ✓    ✓    ✓
  Atomic question                  ✓    ✓    ✓    ✓
  Scope                            ✓    ✓    ✓    ✓
  Patient-facing explanation       ✓    ✓    ✓    ✓
  HER2 treatment concept           ✓    ✓    ✓    ✓
  Trastuzumab                      ✓    ✓    ✓    ✓
  T-DXd                            ✓    ✓    ✓    ✓
  ToGA                             ✓    ✓    ✓    ✓
  KEYNOTE-811                      ✓    ✓    ✓    ✓
  DESTINY-Gastric                  ✓    ✓    ✓    ✓
  Treatment-line context           ✓    ✓    ✓    ✓
  Benefit / limitations            ✓    ✓    ✓    ✓
  Resistance                       ✓    ✓    ✓    ✓
  Safety                           ✓    ✓    ✓    ✓
  Patient questions                ✓    ✓    ✓    ✓
  Knowledge Graph                  ✓    ✓    ✓    ✓
  Boundary                         ✓    ✓    ✓    ✓
  Evidence traceability            ✓    ✓    ✓    ✓
  Adjacent PP overlap              ✓    ✓    ✓    ✓
  QA                               ✓    ✓    ✓    ✓

------------------------------------------------------------------------

# Final QA Status

# PASS --- GOLD --- READY FOR INTEGRATION
